tradingkey.logo
tradingkey.logo
Search

Intellia Completes Global Phase 3 HAELO Study Enrollment for Lonvo-Z in Hereditary Angioedema

ReutersSep 18, 2025 11:39 AM
facebooktwitterlinkedin

- Intellia Therapeutics Inc NTLA.O:

  • INTELLIA THERAPEUTICS COMPLETES ENROLLMENT IN THE GLOBAL PHASE 3 HAELO STUDY OF LONVOGURAN ZICLUMERAN (LONVO-Z) FOR HEREDITARY ANGIOEDEMA

  • INTELLIA THERAPEUTICS INC - PHASE 3 TOPLINE DATA EXPECTED IN FIRST HALF 2026

  • INTELLIA THERAPEUTICS INC: ON TRACK TO SUBMIT BLA IN SECOND HALF OF 2026 FOR AN ANTICIPATED U.S. LAUNCH IN FIRST HALF OF 2027

  • INTELLIA THERAPEUTICS INC: PLAN TO PRESENT ADDITIONAL DATA FROM PHASE 1/2 STUDY IN Q4 OF 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI